GLP-1 fusion proteins
First Claim
Patent Images
1. A heterologous fusion protein comprising a first polypeptide with a N-terminus and a C-terminus fused to a second polypeptide with a N-terminus and a C-terminus wherein the first polypeptide is a GLP-1 compound and the second polypeptide is selected from the group consisting ofa) human albumin;
- b) human albumin analogs; and
c) fragments of human albumin,and wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.
-
Citations
13 Claims
-
1. A heterologous fusion protein comprising a first polypeptide with a N-terminus and a C-terminus fused to a second polypeptide with a N-terminus and a C-terminus wherein the first polypeptide is a GLP-1 compound and the second polypeptide is selected from the group consisting of
a) human albumin; -
b) human albumin analogs; and c) fragments of human albumin, and wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
5. The heterologous fusion protein of claims 1, 2, or 3 wherein the GLP-1 compound comprises the sequence of formula II (SEQ ID NO:
- 3);
- 3);
-
6. The heterologous fusion protein of claims 1, 2, or 3 wherein the GLP-1 compound comprises the sequence of formula III (SEQ ID NO:
- 4);
- 4);
-
7. The heterologous fusion protein of claim 1 wherein the GLP-1 compound has no more than 6 amino acids that are different from the corresponding amino acid in GLP-1(7-37)OH, GLP-1(7-36)OH, or Exendin-4.
-
8. The heterologous fusion protein of claim 7 wherein the GLP-1 compound has no more than 5 amino acids that differ from the corresponding amino acid in GLP-1(7-37)OH, GLP-1(7-36)OH, or Exendin-4.
-
9. The heterologous fusion protein of claim 8 wherein the GLP-1 compound has no more than 4 amino acids that differ from the corresponding amino acid in GLP-1(7-37)OH, GLP-1(7-36)OH, or Exendin-4.
-
10. The heterologous fusion protein of claim 9 wherein the GLP-1 compound has no more than 3 amino acids that differ from the corresponding amino acid in GLP-1(7-37)OH, GLP-1(7-36)OH, or Exendin-4.
-
11. The heterologous fusion protein of claim 10 wherein the GLP-1 compound has no more than 2 amino acids that differ from the corresponding amino acid in GLP-1(7-37)OH, GLP-1(7-36)OH, or Exendin-4.
-
12. A method of treating a patient with non-insulin dependent diabetes mellitus comprising the administration of a therapeutically effective amount of the heterologous fusion protein of claim 1.
-
13. A method of treating obesity comprising the administration of a therapeutically effective amount of the heterologous fusion protein of claim 1.
-
2. A heterologous fusion protein comprising a first polypeptide with a N-terminus terminus and a C-terminus fused to a second polypeptide with a N-terminus and a C-terminus wherein the first polypeptide is a GLP-1 compound and the second polypeptide is selected from the group consisting of
a) human albumin; -
b) human albumin analogs; and c) fragments of human albumin, and wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide via a peptide linker. - View Dependent Claims (3)
-
Specification